Eupraxia Pharmaceuticals Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | $21.3M | $16.1M | $20.4M |
| SG&A Expense | $17.1M | $10.9M | $7.5M |
| Operating Income | $-38.6M | $-25.1M | $-27.8M |
| Operating Margin | — | — | — |
| Interest Expense | $0 | $603.6K | $1.2M |
| Pretax Income | $-38.6M | $-25.7M | $-28.9M |
| Income Tax Expense | $19.1K | $1.8K | $36.4K |
| Net Income | $-38.6M | $-25.5M | $-28.2M |
| Net Margin | — | — | — |
| EPS (Basic) | $-1.03 | $-0.76 | $-1.17 |
| EPS (Diluted) | $-1.03 | $-0.76 | $-1.17 |
| Shares Outstanding (Basic) | 40.0M | 33.9M | 24.1M |
| Shares Outstanding (Diluted) | 40.0M | 33.9M | 24.1M |
| Dividends Per Share | — | — | — |